Instead of the US suspending and firing doctors for sharing information regarding clinical trials, perhaps The RECOVERY Trial's approach would be more beneficial for advancing discussions related to the viability of individual COVID-19 therapeutics.

Fauci and Gates are full aware of these public data sets.

Why isn't the public?

-------

The RECOVERY Trial

https://www.recoverytrial.net/

RECOVERY is a randomised trial investigating whether treatment with either Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Convalescent plasma or Tocilizumab prevents death in patients with COVID-19. In partnership with the Nuffield Department of Population Health, University of Oxford (research encompasses observational epidemiology, randomised controlled trials and health services research across all settings).

Data from the trial are regularly reviewed AND REPORTED, so that any effective treatment can be identified quickly and made available to all patients. Please see our news page for results that RECOVERY has already found. The RECOVERY Trial team will constantly review information on new drugs and include promising ones in the trial.

The RECOVERY Trial is registered at ISRCTN50189673:

http://www.isrctn.com/ISRCTN50189673

EU Clinical Trials Register: EudraCT 2020-001113-21

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB

Clinical Trials.gov: NCT04381936

https://clinicaltrials.gov/ct2/show/NCT04381936

FUNDERS

This trial is supported by a grant to the University of Oxford from UK Research and Innovation/National Institute for Health Research (NIHR) and by core funding provided by NIHR Oxford Biomedical Research Centre, Wellcome,  the Bill and Melinda Gates Foundation, the Department for International Development, Health Data Research UK, the Medical Research Council Population Health Research Unit, and NIHR Clinical Trials Unit Support Funding.

Also see:

Research in the Context of a Pandemic

H. Clifford Lane, M.D., and Anthony S. Fauci, M.D.

July 17, 2020

DOI: 10.1056/NEJMe2024638

https://www.nejm.org/doi/full/10.1056/NEJMe2024638

And another falsified disclosure form submitted by Fauci, stating no conflicts of interest:

https://www.nejm.org/doi/suppl/10.1056/NEJMe2024638/suppl_file/nejme2024638_disclosures.pdf

>>3642

Maybe this is why they are skipping "animal trials" for COVID vaccines. They are specifically trying to alter "HUMAN" DNA to perhaps speed up human evolution to parallel the technocracy agenda. In that respect, "animal trials" would be a waste of resources. Just a theory.

DARPA pioneered the use of the body as a bioreactor to produce prophylactic antibodies to protect against biothreats.

THE DARPA SOLUTION (an excerpt from the article)

In 2012 with the ADEPT:PROTECT program*, DARPA began investing in the development of gene-encoded vaccines, a new category of preventive measures based on DNA or RNA. In this approach, genes that encode immune stimulating antigens, such as the spike proteins on the surfaces of viruses like the one (SARS-CoV-2) that causes COVID-19, are delivered directly to a recipient’s body. There, the instructions carried in the DNA or RNA elicit the body’s own cells to manufacture the antigenic viral protein, which, in turn, elicits an immune response to the virus.

Gene-based vaccines have shown great promise as a means to provide safe, reproducible, long-term immune protection. For vaccines to work, however, they often require more than one dose and it often takes weeks to months before a recipient’s immune system builds up sufficient protection against the vaccine’s viral target.

With these biomedical realities come threats to warfighters if they deploy to pathogen-rife regions before having established relevant immunity and threats to military missions due to delayed deployment of personnel until they achieve immune protection.

For a vaccine to confer immunity, it must lead to the production within a recipient of highly potent antibodies that can neutralize the pathogen. DARPA initiated the ADEPT:PROTECT program (most often referred to more simply as ADEPT) with the intention of bushwhacking a novel pathway to near-immediate protection against pathogens for which vaccines are not yet available and to confer interim-term protection during the development of a vaccine, WHICH CAN TAKE YEARS.

THE IMPACT

DARPA’s investments in this space led directly, with the biotechnology firm Moderna as a contracted performer on the program, to a first-ever human clinical trial with an RNA vaccine in 2019. Earlier proof-of-concept experiments funded under ADEPT primarily with 6.1 funding (for basic research) demonstrated that delivery of antibodymaking instructions — by way of messenger ribonucleic acid (mRNA), deoxyribonucleic acid (DNA), or another genetic-information-carrying tactic that relies on small viruses known as adenovirus-associated viruses (AAVs) — led to the production of antibodies that conferred protection in test animals exposed to the mosquito-borne Chikungunya (ChikV) virus.

Moderna subsequently used company funding to conduct a Phase I clinical trial with 22 healthy volunteers using an mRNA-encoded ChikV antibody. This marked the first safety demonstration of an RNA-based medical countermeasure. Moderna reported these promising results of its clinical study in 2019. The trial demonstrated platform safety as well as the ability to generate protective levels of functional antibody in humans.

In response to COVID-19, Moderna in March 2020 initiated human trials of gene-encoded antibodies that target SARS-CoV-2. Research by Moderna and other ADEPT performers has provided proof-of-concept results that simultaneously delivering gene-encoded antibody treatment and vaccine confers the recipient with immediate immune protection while a long-term immune response develops.

ADEPT investments also were foundational to an ambitious followon DARPA program, the Pandemic Prevention Platform (P3). Its goal is to prevent pandemic outbreaks by creating a platform capable of identifying, testing, and mass-producing MCMs within 60 days of the detection of an outbreak. The emergence of COVID-19 in late 2019 and its pandemic spread in 2020 reinforced the importance of ADEPT and P3 in the most forceful of terms possible. P3 is part of a yet more comprehensive portfolio of DARPA programs that stand a chance of ultimately delivering a technology framework that could quash just about any outbreak of a known or emerging infectious disease before it

could grow into a pandemic.

https://www.darpa.mil/attachments/ADEPTVignetteFINAL.pdf